Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
NCT ID: NCT00685737
Last Updated: 2008-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2007-12-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Main purpose of this study is to formally evaluate the safety and pharmacokinetics and pharmacodynamics of 1-MNA, a hypolipidemic agent with previous human exposure in normal subjects and patients with Hyperlipidemia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
1-MNA-Low Dose
1-MNA
Capsule
2
1-MNA-High Dose
1-MNA
Capsule
3
Placebo
Placebo
Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1-MNA
Capsule
Placebo
Capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the Screening visit)
* Between 18 and 50 years old (inclusive)
* Body weight within 20% of the desirable weight for adults at the Screening visit
* Able to execute informed written consent (informed consent must be obtained for all subjects before enrollment in the study.
* Willingness to abstain from alcohol and xanthine-containing food and beverages for the duration of each treatment period
* Willingness to remain in the clinic for the inpatient portions of the study
* Female subjects must be non-pregnant and either surgically sterile, postmenopausal for a least 1 year, or using an acceptable method of contraception defined as an oral, implanted, or transdermal contraceptive plus one of the following barrier methods: diaphragm with spermicidal cream/jelly or use of a condom by sexual partner.
Exclusion Criteria
* Unwilling or unable to comply with the protocol or reside in the study unit during the study period or to cooperate fully with the principal investigator and site personnel
* Has used any 1) prescription medication within 14 days prior to treatment in either treatment period or 2), or any over-the-counter (OTC) medication, herbal preparations, and/or vitamins within 48 hours prior to the start of study MNA administration on either treatment period of this study.
* Has a clinically abnormal ECG
* Has a serum potassium, sodium, calcium, or magnesium level that is not within normal limits or has other vital signs or clinical laboratory values at the screening visit that are deemed by the principal investigator to make the subject an inappropriate candidate for the study
* Has taken any other investigational drug during the 30 days prior to screening visit
* Has donated or lost more than a unit of blood within 30 days prior to screening visit
* History of renal, hepatic, gastrointestinal, cardiovascular, or hematologic disease
* Serious mental or physical illness within the past year
* Has any condition(s) that in the investigator's opinion would: a) warrant exclusion from the study or b) prevent the subject from completing the study
* Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody at screening
* Be a female subject with a positive serum pregnancy test or who is breast-feeding at screening
* Be unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent is available
* Has a history of hypersensitivity or allergic reaction to Niacin or Nicotinamide
* Has had prior exposure to MNA
* Has a Mental capacity that is limited to the extent that the subject cannot provide legal consent or understand information regarding the side effects or tolerance of the study drug.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmena North America
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Buffalo Clinical Research Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles H Ballow, Pharm D.
Role: PRINCIPAL_INVESTIGATOR
Buffalo Clinical Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Buffalo Clinical Research Center
Buffalo, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PNAI-002
Identifier Type: -
Identifier Source: org_study_id